QuidelOrtho Corporation (QDEL)
QDEL Stock Price Chart
Explore QuidelOrtho Corporation interactive price chart. Choose custom timeframes to analyze QDEL price movements and trends.
QDEL Company Profile
Discover essential business fundamentals and corporate details for QuidelOrtho Corporation (QDEL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
IPO Date
1 Feb 1991
Employees
6.60K
Website
https://www.quidelortho.comCEO
Brian J. Blaser
Description
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
QDEL Financial Timeline
Browse a chronological timeline of QuidelOrtho Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.62, while revenue estimate is $667.45M.
Earnings released on 5 Aug 2025
EPS came in at $0.12 falling short of the estimated $0.56 by -78.61%, while revenue for the quarter reached $615.10M , missing expectations by -9.08%.
Earnings released on 7 May 2025
EPS came in at $0.74 surpassing the estimated $0.58 by +27.59%, while revenue for the quarter reached $692.80M , beating expectations by +0.13%.
Earnings released on 12 Feb 2025
EPS came in at $0.63 surpassing the estimated $0.55 by +14.55%, while revenue for the quarter reached $707.80M , missing expectations by -1.44%.
Earnings released on 7 Nov 2024
EPS came in at $0.85 surpassing the estimated $0.31 by +174.19%, while revenue for the quarter reached $727.10M , beating expectations by +4.16%.
Earnings released on 31 Jul 2024
EPS came in at -$0.07 surpassing the estimated -$0.21 by +66.67%, while revenue for the quarter reached $636.30M , missing expectations by -0.90%.
Earnings released on 8 May 2024
EPS came in at $0.44 surpassing the estimated $0.43 by +2.33%, while revenue for the quarter reached $709.70M , beating expectations by +2.11%.
Earnings released on 13 Feb 2024
EPS came in at $1.17 falling short of the estimated $2.02 by -42.08%, while revenue for the quarter reached $742.60M , missing expectations by -6.82%.
Earnings released on 1 Nov 2023
EPS came in at $0.90 surpassing the estimated $0.45 by +100.00%, while revenue for the quarter reached $744.00M , beating expectations by +7.53%.
Earnings released on 8 Aug 2023
EPS came in at $0.26 surpassing the estimated $0.25 by +4.00%, while revenue for the quarter reached $665.10M , beating expectations by +8.13%.
Earnings released on 3 May 2023
EPS came in at $1.80 surpassing the estimated $1.40 by +28.57%, while revenue for the quarter reached $846.10M , beating expectations by +16.99%.
Earnings released on 15 Feb 2023
EPS came in at $1.76 surpassing the estimated $1.40 by +25.71%, while revenue for the quarter reached $866.50M , beating expectations by +12.45%.
Earnings released on 2 Nov 2022
EPS came in at $1.85 surpassing the estimated $0.60 by +208.33%, while revenue for the quarter reached $783.80M , beating expectations by +8.92%.
Earnings released on 4 Aug 2022
EPS came in at $2.12 falling short of the estimated $3.69 by -42.55%, while revenue for the quarter reached $613.40M , missing expectations by -20.15%.
Earnings released on 4 May 2022
EPS came in at $11.66 surpassing the estimated $9.89 by +17.90%, while revenue for the quarter reached $1.00B , beating expectations by +12.48%.
Earnings released on 17 Feb 2022
EPS came in at $7.29 surpassing the estimated $5.61 by +29.95%, while revenue for the quarter reached $636.87M , beating expectations by +17.74%.
Earnings released on 4 Nov 2021
EPS came in at $5.36 surpassing the estimated $3.52 by +52.27%, while revenue for the quarter reached $509.74M , beating expectations by +188.07%.
Earnings released on 5 Aug 2021
EPS came in at $0.75 falling short of the estimated $1.20 by -37.50%, while revenue for the quarter reached $176.61M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at $4.38 falling short of the estimated $4.71 by -7.01%, while revenue for the quarter reached $375.34M , missing expectations by -19.49%.
Earnings released on 18 Feb 2021
EPS came in at $11.07 surpassing the estimated $10.14 by +9.17%, while revenue for the quarter reached $809.20M , missing expectations by -0.74%.
Earnings released on 29 Oct 2020
EPS came in at $5.78 surpassing the estimated $4.75 by +21.68%, while revenue for the quarter reached $476.06M , beating expectations by +21.68%.
QDEL Stock Performance
Access detailed QDEL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.